Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer's disease.

Alzheimers Res Ther · 2026 · PMC13182022 · PMID 41943055

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

nominally significantp ≤ 0.10so close (0.05 < p ≤ 0.1)

Nominally significant trends (p ≤ 0.10) in reducing plasma levels of Aβ40, Aβ42, and NfL were also observed in zervimesine vs. placebo treated participants, which provides support for a role of zervimesine in impacting amyloid biology, neuroinflammation and neurodegeneration in patients with mild to moderate AD that have lower than 1 pg/ml p-tau17 levels at baseline using the AlzPath Dx assay.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.